Newly Independent, Microarrays Inc. Sets Sights on Molecular Diagnostics Market

According to CEO Joel Peek, MI's change in ownership reflects a shift in its business plans. While it has served as an array foundry for research and diagnostic customers for a decade, it is now seeking to apply its expertise in assay design to the clinical market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.